Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults

References

• Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36(1):53-9
   PubMed Web of Science ®Google Scholar
• Song X, Perencevich E, Campos J, et al. Clinical and economic impact of methicillin-resistant Staphylococcus aureus colonization or infection on neonates in intensive care units. Infect Control Hosp Epidemiol 2010;31(2):177-82
   PubMedGoogle Scholar
• Dantes R, Mu Y, Belflower R, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections. United States, 2011. JAMA Intern Med 2013;173(21):1970-8
   PubMed Web of Science ®Google Scholar
• Herigon JC, Hersh AL, Gerber JS, et al. Antibiotic management of Staphylococcus aureus infections in US children’s hospitals, 1999–2008. Pediatrics 2010;125(6):e1294-300
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Mu Y, Lynfield R, et al. Trends in invasive methicillin-resistant Staphylococcus aureus infections. Pediatrics 2013;132(4):e817-24
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349(12):1157-67
   PubMed Web of Science ®Google Scholar
• DailyMed. U.S. National Library of Medicine, Bethesda, MD, 2013. Available from: http://dailymed.nlm.nih.gov/
   Google Scholar
• Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997;41(10):2127-31
   PubMed Web of Science ®Google Scholar
• Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998;42(12):3251-5
   PubMed Web of Science ®Google Scholar
• Pharmacia and Upjohn Company. (2013). Zyvox (linezolid), package insert. Kalamazoo, MI, USA
   Google Scholar
• Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40(4):839-45
   PubMed Web of Science ®Google Scholar
• Welshman IR, Sisson TA, Jungbluth GL, et al. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 2001;22(3):91-7
   PubMed Web of Science ®Google Scholar
• Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003;42(13):1129-40
   PubMed Web of Science ®Google Scholar
• Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003;51(5):1239-46
   PubMed Web of Science ®Google Scholar
• Leach KL, Brickner SJ, Noe MC, Miller PF. Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci 2011;1222:49-54
   PubMed Web of Science ®Google Scholar
• Slatter JG, Stalker DJ, Feenstra KL, et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab Dispos 2001;29(8):1136-45
   PubMed Web of Science ®Google Scholar
• Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003;22(9 Suppl):S153-7
   PubMed Web of Science ®Google Scholar
• Wible K, Tregnaghi M, Bruss J, et al. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J 2003;22(4):315-23
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant gram-positive infections in children. Pediatr Infect Dis J 2003;22(8):677-86
   PubMed Web of Science ®Google Scholar
• Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003;22(9 Suppl):S158-63
   PubMedGoogle Scholar
• Cubist Pharmaceuticals Inc. (2013). Cubicin (daptomycin), package insert. Lexington, MA, USA
   Google Scholar
• Oberholzer CM, Caserta MT. Antimicrobial update: daptomycin. Pediatr Infect Dis J 2005;24(10):919-20
   PubMedGoogle Scholar
• Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J Antimicrob Chemother 2005;55(3):283-8
   PubMed Web of Science ®Google Scholar
• Critchley IA, Draghi DC, Sahm DF, et al. Activity of daptomycin against susceptible and multidrug-resistant gram-positive pathogens collected in the SECURE study (Europe) during 2000–2001. J Antimicrob Chemother 2003;51(3):639-49
   PubMed Web of Science ®Google Scholar
• Dvorchik B, Damphousse D. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J Clin Pharmacol 2004;44(6):612-20
   PubMedGoogle Scholar
• Dvorchik B, Arbeit RD, Chung J, et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004;48(8):2799-807
   PubMedGoogle Scholar
• Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50(10):3245-9
   PubMed Web of Science ®Google Scholar
• Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47(4):1318-23
   PubMed Web of Science ®Google Scholar
• Liang SH, Sheng WH, Huang YT, et al. Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population. Chemotherapy 2009;55(2):91-6
   PubMedGoogle Scholar
• Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008;27(4):330-4
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Watt KM, Hornik CP, et al. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J 2012;31(9):935-7
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Smith PB, Benjamin DK Jr, et al. Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J Perinatol 2008;28(3):233-4
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38(12):1673-81
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355(7):653-65
   PubMed Web of Science ®Google Scholar
• Ardura MI, Mejias A, Katz KS, et al. Daptomycin therapy for invasive gram-positive bacterial infections in children. Pediatr Infect Dis J 2007;26(12):1128-32
   PubMedGoogle Scholar
• Antachopoulos C, Iosifidis E, Sarafidis K, et al. Serum levels of daptomycin in pediatric patients. Infection 2012;40(4):367-71
   PubMedGoogle Scholar
• ClinicalTrials.gov. U.S. National Institutes of Health, Silver Spring, MD, 2013. Available from: http://clinicaltrials.gov
   Google Scholar
• Pfizer Laboratories. (2013). Synercid (quinupristin and dalfopristin injection), package insert. New York, NY, USA
   Google Scholar
• Cocito C, Di Giambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 1997;39(Suppl A):7–13.
   PubMedGoogle Scholar
• Gaillad C VCJ, Montay G, et al. Disposition of the radiolabelled streptogramin RP 59500 in healthy male volunteers. Presented at: 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, USA; 1992
   Google Scholar
• Bergeron M, Montay G. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J Antimicrob Chemother 1997;39(Suppl A):129-38
   PubMedGoogle Scholar
• Chevalier P, Rey J, Pasquier O, et al. Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (Synercid) in healthy volunteers. J Clin Pharmacol 2001;41(4):404-14
   PubMed Web of Science ®Google Scholar
• Chevalier P, Rey J, Pasquier O, et al. Pharmacokinetics of quinupristin/dalfopristin in patients with severe chronic renal insufficiency. Clin Pharmacokinet 2000;39(1):77-84
   PubMedGoogle Scholar
• Chevalier PR, Boucher E, et al. Open, comparative, study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D), RP 59500, Synercid) in subjects with hepatic cirrhosis and healthy volunteers. Presented at: 20th International Congress of Chemotherapy. Sydney, Australia; 1997
   Google Scholar
• Lefebvre PR, Harding N, et al. Open, comparative study of the pharmacokinetic and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) in healthy elderly volunteers and healthy young volunteers. Presented at: 20th International Congress of Chemotherapy, Sydney, Australia; 1997
   Google Scholar
• Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999;44(2):263-73
   PubMed Web of Science ®Google Scholar
• Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999;44(2):251-61
   PubMedGoogle Scholar
• Loeffler AM, Drew RH, Perfect JR, et al. Safety and efficacy of quinupristin/dalfopristin for treatment of invasive gram-positive infections in pediatric patients. Pediatr Infect Dis J 2002;21(10):950-6
   PubMedGoogle Scholar
• Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000;161(3 Pt 1):753-62
   PubMed Web of Science ®Google Scholar
• Verma A, Dhawan A, Philpott-Howard J, et al. Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients: safety and clinical efficacy of quinupristin/dalfopristin. J Antimicrob Chemother 2001;47(1):105-8
   PubMedGoogle Scholar
• Plotkin P, Patel K, Uminski A, Marzella N. Telavancin (vibativ), a new option for the treatment of gram-positive infections. P T 2011;36(3):127-38
   PubMedGoogle Scholar
• Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49(3):1127-34
   PubMed Web of Science ®Google Scholar
• Lunde CS, Hartouni SR, Janc JW, et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009;53(8):3375-83
   PubMed Web of Science ®Google Scholar
• Krause KM, Renelli M, Difuntorum S, et al. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 2008;52(7):2647-52
   PubMedGoogle Scholar
• Mendes RE, Sader HS, Farrell DJ, Jones RN. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of gram-positive clinical pathogens from five continents. Antimicrob Agents Chemother 2012;56(7):3999-4004
   PubMed Web of Science ®Google Scholar
• Theravance. (2012). VIBATIV (telavancin hydrochloride), package insert. San Francisco, CA, USA
   Google Scholar
• Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49(1):195-201
   PubMed Web of Science ®Google Scholar
• Barcia-Macay M, Mouaden F, Mingeot-Leclercq MP, et al. Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J Antimicrob Chemother 2008;61(6):1288-94
   PubMedGoogle Scholar
• Wong SL, Barriere SL, Kitt MM, Goldberg MR. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 2008;62(4):780-3
   PubMedGoogle Scholar
• Stryjewski ME, Chu VH, O’Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50(3):862-7
   PubMedGoogle Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46(11):1683-93
   PubMed Web of Science ®Google Scholar
• Barriere SL. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol 2010;5(12):1765-73
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011;52(1):31-40
   PubMed Web of Science ®Google Scholar
• Biek D, Critchley IA, Riccobene TA, Thye DA. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-gram-positive activity. J Antimicrob Chemother 2010;65(Suppl 4):iv9-16
   PubMed Web of Science ®Google Scholar
• Sader HS, Fritsche TR, Kaniga K, et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005;49(8):3501-12
   PubMed Web of Science ®Google Scholar
• Jones RN, Fritsche TR, Ge Y, et al. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005;56(6):1047-52
   PubMed Web of Science ®Google Scholar
• Forest Laboratories. (2013). Teflaro (ceftaroline fosamil), package insert. St. Louis, MO, USA
   Google Scholar
• Riccobene TA, Su SF, Rank D. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrob Agents Chemother 2013;57(3):1496-504
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51(10):3612-16
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65(Suppl 4):iv41-51
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65(Suppl 4):iv53-65
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;51(6):641-50
   PubMed Web of Science ®Google Scholar
• File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011;66(Suppl 3):iii19-32
   PubMed Web of Science ®Google Scholar
• Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011;66(Suppl 3):iii33-44
   PubMed Web of Science ®Google Scholar
• Olson MW, Ruzin A, Feyfant E, et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 2006;50(6):2156-66
   PubMed Web of Science ®Google Scholar
• Wyeth Pharmaceuticals. (2013). Tygacil (tigecycline injection), package insert. Philadelphia, PA, USA
   Google Scholar
• Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000;20(9 Pt 2):219S-23S; discussion 224S–228S
   PubMedGoogle Scholar
• Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000;44(8):2225-9
   PubMedGoogle Scholar
• Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49(1):220-9
   PubMed Web of Science ®Google Scholar
• Muralidharan G, Fruncillo RJ, Micalizzi M, et al. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005;49(4):1656-9
   PubMed Web of Science ®Google Scholar
• Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007;51(6):1939-45
   PubMed Web of Science ®Google Scholar
• Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012;34(2):496-507; e491
   PubMed Web of Science ®Google Scholar
• Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008;62(Suppl 1):i17-28
   PubMed Web of Science ®Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53
   PubMed Web of Science ®Google Scholar
• Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54(12):1699-709
   PubMed Web of Science ®Google Scholar
• Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012;34(2):496-507; e491
   PubMed Web of Science ®Google Scholar
• Laughon MM, Benjamin DK Jr, Capparelli EV, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol 2011;4(5):643-52
   PubMedGoogle Scholar
• Capparelli E, Hochwald C, Rasmussen M, et al. Population pharmacokinetics of cefepime in the neonate. Antimicrob Agents Chemother 2005;49(7):2760-6
   PubMed Web of Science ®Google Scholar
• Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008;52(11):4043-9
   PubMed Web of Science ®Google Scholar
• Pullen J, Stolk LM, Nieman FH, et al. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates. Ther Drug Monit 2006;28(2):226-31
   PubMed Web of Science ®Google Scholar
• Novel antibiotics pipeline. BioCentury Publications, Redwood City, CA, 2014. Available from: http://biocentury/antibioticspipeline/htm
   Google Scholar
• Pediatric Research Equity Act. 108th Congress of the United States of America, 3 December 2003: Statute 117-1936–1943
   Google Scholar